Teva Pharmaceutical Industries

Generics + branded

TEVA · NYSE · Israel

Share price · TEVA

$42.23+5.65 (+15.45%) 3M

close as of 2026-11-18 · 24h delayed · vol 8.9M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TEVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Jul 2026+9.6%
  2. 29 Apr 2026+11.9%
  3. 4 Feb 2026-3.6%

    Nothing announced by TEVA that day or the session before.

Share of unusual movement by asset

For each asset, the share of TEVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Risperidone (Uzedy) (Uzedy)
events and moves
3shown from 8 days
Olanzapine (Weltruza) (Weltruza)
events and moves
3shown from 8 days
Dexmedetomidine (Igalmi) (Igalmi)
events and moves
3shown from 8 days
duvakitug
events and moves
2shown from 8 days
Emrusolmin
events and moves
1shown from 8 days
ustekinumab-aekn (Selarsdi) (Selarsdi)
events and moves
1shown from 8 days
Fremanezumab (Ajovy) (Ajovy)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—33%
Sessions with no dated event—65%

Assets

(13 total)
13Total Assets
10Approved
2Phase 3 / Filed
1Phase 1–2 / Early
16Diseases
Quick filter:
Showing 13 of 13 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
Glucocorticoid receptorSmall molecule
Asthma
Approved
Myelin basic protein-mimetic immunomodulationPeptide
Multiple Sclerosis
Approved
CGRP ligandMonoclonal antibody
Migraine
Approved
Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Small molecule
Schizophrenia
Approved
MAO-BSmall molecule
Parkinson's Disease
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Approved
CD20Monoclonal antibody
Rheumatoid ArthritisNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Approved
GABA transporter (uptake carrier)Small molecule
Epilepsy
Focal Onset Seizures
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Phase 3
Alpha-2 adrenergic receptor (agonist)Small molecule
SchizophreniaBipolar DisorderAlzheimer's Disease
Alzheimer's Disease Agitation
Phase 3
TL1AMonoclonal antibody
Inflammatory Bowel DiseaseHidradenitis Suppurativa
Ulcerative Colitis, Crohn's Disease
Phase 1
alpha-synuclein oligomersSmall molecule
Parkinson's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
EmrusolminPhase 2Multiple System Atrophy
Est. primary completion 2027-09-15 · NCT06568237 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
duvakitugPhase 3Ulcerative Colitis
Est. primary completion 2028-05-09 · NCT07184996 · CT.gov ↗
What to watch
June 2028 (1)
duvakitugPhase 2Hidradenitis
Est. primary completion 2028-06-16 · NCT07812116 · CT.gov ↗
What to watch
September 2028 (1)
duvakitugPhase 3Ulcerative Colitis
Est. primary completion 2028-09-21 · NCT07185009 · CT.gov ↗
What to watch
2029 (3)
May 2029 (2)
EmrusolminPhase 2Multiple System Atrophy
Est. primary completion 2029-05-03 · NCT07197866 · CT.gov ↗
What to watch
duvakitugPhase 3Crohn's Disease
Est. primary completion 2029-05-14 · NCT07184931 · CT.gov ↗
What to watch
August 2029 (1)
duvakitugPhase 3Crohn's Disease
Est. primary completion 2029-08-13 · NCT07184944 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalDexmedetomidine (Igalmi)FDA approves IGALMI for at-home use
US, FDA · Source ↗
2 November 2026Topline resultEmrusolminTOPAS-MSA stopped after its interim futility analysis
Teva Pharmaceutical Industries · Source ↗
9 October 2026ApprovalOlanzapine (TV-44749)FDA approves WELTRUZA for schizophrenia
US, FDA · Teva Pharmaceuticals · Source ↗
8 October 2026ApprovalOlanzapine (Weltruza)FDA Boxed Warning on Weltruza (NDA219007)
US, FDA · FDA · Source ↗
May 2026Filing acceptedOlanzapine (TV-44749)EMA accepts MAA for olanzapine LAI
EU, EMA · Teva Pharmaceuticals · Source ↗
14 January 2026Filing submittedDexmedetomidine (Igalmi)sNDA submitted for at-home IGALMI
US, FDA · Source ↗

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$4.4B$297M$4.1B—$241M operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$4.1B$970M$3.7B$576M$411M operating cash flowreport ↗
2026-Q1$4.0B$222M$3.7B—report ↗
2025-Q4$4.7B$267M$3.6B—report ↗
2025-Q3$4.5B$256M$2.2B—report ↗
2025-Q2$4.2B$244M$2.2B—report ↗
2025-Q1$3.9B$247M$1.7B—report ↗
2024-Q4$4.2B$248M$3.3B—report ↗
2024-Q3$4.3B$240M$3.3B—report ↗
2024-Q2$4.2B$269M$2.3B—report ↗
2024-Q1$3.8B$242M$3.0B$139M-$124M operating cash flowreport ↗
2023-Q3$3.9B$253M$2.3B—$5.0M operating cash flowreport ↗
2023-Q2$3.9B$240M$2.7B$863M$324M operating cash flowreport ↗
2023-Q1$3.7B$234M$2.2B$205M-$145M operating cash flowreport ↗
2022-Q4——$2.8B$1.3B$973M operating cash flowreport ↗
2022-Q3$3.6B$175M$2.3B—$543M operating cash flowreport ↗
2022-Q2$3.8B$228M$2.1B$232M$123M operating cash flowreport ↗
2022-Q1$3.7B$225M$2.3B$955M-$49M operating cash flowreport ↗
2021-Q3$3.9B$222M$2.0B—$529M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$17.3B$1.0B$3.6B—report ↗

Teva reported FY2025 revenue of $17,258M, up 4.3% YoY, with R&D spend of $1,013M, up 1.5% YoY. Cash and equivalents stood at $3,556M, and the company recorded net income of $1,410M.

The 2025 results included a $500M development milestone received in the fourth quarter upon initiation of Phase 3 studies for duvakitug (anti-TL1A). During the year, Teva issued senior notes totaling $700M, €1,000M, and $500M, repaid several series of senior notes at maturity, and extinguished additional notes through a cash tender offer. It also entered into a $500M notional fixed-to-fixed cross-currency interest rate swap to hedge USD-denominated debt.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$16.5B$998M$3.3B—report ↗
2023-FY$15.8B$953M$3.2B—report ↗
2022-FY$14.9B$838M$2.8B—report ↗
2021-FY$15.9B$967M$2.2B—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 64 sales ($124.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-15Bergwerk Dov · Interim Chief Legal OfficerOption exercise8,370——Form 4
2026-11-15Bergwerk Dov · Interim Chief Legal OfficerOption exercise (derivative)8,370——Form 4
2026-11-12Sabag Mark · See "Remarks"Option exercise44,710$34.90$1.6MForm 4
2026-11-12Sabag Mark · See "Remarks"Open-market sale44,710$44.14$2.0MForm 4
2026-11-12Sabag Mark · See "Remarks"Option exercise (derivative)44,710——Form 4
2026-11-11Daniell Richard · EVP, Europe CommercialOption exercise20,003$34.70$694KForm 4
2026-11-11Daniell Richard · EVP, Europe CommercialOpen-market sale20,003$42.80$856KForm 4
2026-11-11Daniell Richard · EVP, Europe CommercialOption exercise (derivative)20,003——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 647 reporting institutions held 673.8M shares ($16.9B, 57.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.65,136,464$2.0B
2Phoenix Financial Ltd.42,777,414$1.3B
3MENORA MIVTACHIM HOLDINGS LTD.39,626,383$1.2B
4WCM INVESTMENT MANAGEMENT, LLC40,820,600$1.2B
5Migdal Insurance & Financial Holdings Ltd.37,902,212$1.1B
6FMR LLC33,132,795$998.0M
7Lingotto Investment Management LLP27,770,857$836.5M
8STATE STREET CORP17,790,020$535.8M
9Rubric Capital Management LP15,250,000$459.3M
10Altshuler Shaham Ltd11,463,621$334.6M
11GEODE CAPITAL MANAGEMENT, LLC10,564,988$316.3M
12Capital World Investors8,833,566$266.1M
13NORTHERN TRUST CORP7,635,688$230.0M
14MORGAN STANLEY7,426,253$223.7M
15WELLINGTON MANAGEMENT GROUP LLP7,251,828$218.4M